Matthew Blischak
Algemeen Directeur bij FINCH THERAPEUTICS GROUP, INC.
Vermogen: - $ op 30-04-2024
Actieve functies van Matthew Blischak
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Algemeen Directeur | 16-05-2023 | - |
| President | 16-05-2023 | - | |
| Bedrijfssecretaris | 16-05-2023 | - |
Loopbaan van Matthew Blischak
Eerdere bekende functies van Matthew Blischak
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-05-2018 | 01-04-2023 |
Opleiding van Matthew Blischak
| Case Western Reserve University | Undergraduate Degree |
| American University Washington College of Law | Graduate Degree |
| The Johns Hopkins University | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Graduate Degree | 2 |
| Chief Executive Officer | 1 |
| President | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Services | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Bedrijven in privébezit | 1 |
|---|---|
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
- Beurs
- Insiders
- Matthew Blischak
- Ervaring
